A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the preliminary safety and immunogenicity
(ability of an antigen to provoke immune response in the human body) of CNTO 2476,
administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of
the eye that leads to loss of vision and blindness) with either light perception only (LP) or
hand motion (HM).